38 completed. 38 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Completed 38 |
| Phase 2 | 3 | Completed 3 |
Follow Tinea: new trials by email Literature Review of Tinea trials Research Report on Tinea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Essential Oils as Natural Therapies application of cream "La Chinata" - Dermatophytoses, Skin Lesion | Phase 3 | Completed | University of Extremadura | 49 | 2023-02-11 | 2023-12-15 |
| A Therapeutic Equivalence Study of Ketoconazole Cream 2% Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.) - Tinea Pedis | Phase 3 | Completed | Douglas Pharmaceuticals America Ltd | 682 | 2019-12-11 | 2020-08-06 |
| Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis Candicort®, Nizoral®, Baycuten N® - Tinea | Phase 3 | Completed | Ache Laboratorios Farmaceuticos S.A. | 125 | 2019-06-11 | 2021-09-20 |
| Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo - Tinea Pedis | Phase 3 | Completed | Encube Ethicals Pvt. Ltd. | 831 | 2018-08-23 | 2019-06-27 |
| Non-inferiority Trial of Dapaconazole Versus Ketoconazole Dapaconazole, Ketoconazole - Tinea Pedis | Phase 3 | Completed | Biolab Sanus Farmaceutica | 360 | 2017-11-01 | 2020-07-27 |
| Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Efinaconazole Topical - Onychomycosis | Phase 3 | Completed | Western University of Health Sciences | 40 | 2017-06-06 | 2020-10-30 |
| Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Econazole Nitrate Cream, 1%, Placebo - Tinea Pedis | Phase 3 | Completed | Mylan Inc. | 876 | 2016-03-15 | 2022-03-07 |
| Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis P-3058 10%, vehicle of P-3058 10%, amorolfine 5% - Onychomycosis | Phase 3 | Completed | Polichem S.A. | 953 | 2015-08-20 | 2018-09-26 |
| Design and Clinical Evaluation of a School Meal With Deworming Properties Ujiplus, Albendazole, uji - Helminthiasis, Tinea Capitis | Phase 2 / Phase 3 | Completed | Kenya Medical Research Institute | 326 | 2015-05-01 | 2016-09-07 |
| BE Study of Naftifine HCL Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%) - Tinea Pedis | Phase 3 | Completed | Genzum Life Sciences | 693 | 2015-03-01 | 2017-05-11 |
| Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population P-3058 - Onychomycosis | Phase 3 | Completed | Polichem S.A. | 20 | 2014-08-01 | 2018-03-08 |
| Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Naftin 1% Cream, Placebo Cream - Tinea Cruris, Jock Itch | Phase 3 | Completed | Merz North America, Inc. | 65 | 2013-08-01 | 2015-04-15 |
| Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Luliconazole Solution, 10%, Vehicle Solution - Distal and Lateral Subungual Onychomycosis | Phase 2 / Phase 3 | Completed | Topica Pharmaceuticals | 334 | 2012-05-01 | 2015-11-30 |
| Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Terbinafine, Terbinafine Placebo - Tinea Pedis | Phase 3 | Completed | Novartis | 290 | 2011-08-01 | 2013-12-27 |
| Topical Antifungal Treatment for Tinea Pedis 33525, Placebo - Tinea Pedis | Phase 3 | Completed | Medicis Global Service Corporation | 321 | 2011-07-01 | 2013-08-28 |
| Topical Antifungal Treatment for Tinea Pedis 33525, Placebo - Tinea Pedis | Phase 3 | Completed | Medicis Global Service Corporation | 322 | 2011-07-01 | 2013-08-28 |
| Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1% - Tinea Pedis, Athlete's Foot | Phase 3 | Completed | AmDerma | 336 | 2011-06-01 | 2012-09-28 |
| Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Product 33525 - Tinea Pedis, Tinea Cruris | Phase 3 | Completed | Tinea Pharmaceuticals | 604 | 2011-05-01 | 2013-01-23 |
| Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Econazole Nitrate Foam 1%, Vehicle Foam - Tinea Pedis, Athlete's Foot | Phase 3 | Completed | AmDerma | 264 | 2011-05-01 | 2013-01-09 |
| Topical Antifungal Treatment for Tinea Cruris 33525, Placebo - Tinea Cruris | Phase 3 | Completed | Medicis Global Service Corporation | 483 | 2011-05-01 | 2013-08-28 |
Showing 20 of 38. Sign in to see all of them.
Tinea Pedis (15) · Onychomycosis (14) · Foot Dermatoses (5) · Mycoses (4) · Tinea Capitis (4) · Tinea Cruris (4) · Keratoderma, Palmoplantar, Epidermolytic (2) · Nails, Malformed (2) · Onycholysis (2) · Twenty-Nail Dystrophy (2) · Yellow Nail Syndrome (2) · Anemia (1) · Cellulitis (1) · Dermatomycoses (1)
Bacterial Infections and Mycoses (38) · Infections (38) · Skin Diseases (38) · Skin Diseases, Infectious (38) · Skin and Connective Tissue Diseases (38) · Dermatomycoses (37) · Mycoses (34) · Foot Diseases (20) · Pathological Conditions, Signs and Symptoms (18) · Foot Dermatoses (15) · Pruritus (15) · Signs and Symptoms (15) · Skin Manifestations (15) · Nail Diseases (14)
Terbinafine (6) · naftifine (4) · Gels (2) · Ketoconazole (2) · Solutions (2) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (1) · Albendazole (1) · Calcium Dobesilate (1) · Clotrimazole (1) · Fluconazole (1) · Griseofulvin (1) · Itraconazole (1) · amorolfine (1) · betamethasone-17,21-dipropionate (1) · dexamethasone acetate (1)
Merz North America, Inc. (5) · Medicis Global Service Corporation (3) · Novartis (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · AmDerma (2) · Dow Pharmaceutical Sciences (2) · Polichem S.A. (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Bayer (1) · Biolab Sanus Farmaceutica (1) · Douglas Pharmaceuticals America Ltd (1) · Encube Ethicals Pvt. Ltd. (1) · Genzum Life Sciences (1) · Kenya Medical Research Institute (1)
United States (26) · Belize (6) · Canada (6) · Puerto Rico (6) · Germany (5) · Honduras (4) · Dominican Republic (3) · Iceland (3) · Poland (3) · Spain (3) · Belgium (2) · Brazil (2) · Czechia (2) · El Salvador (2) · France (2)
Lawrence Parish, MD (3) · Ron Staugaard (3) · Daniel Piacquadio, MD (2) · Maurizio Caserini, MD (2) · Bernard Goffe, MD (1) · David M Harris, PhD (1) · Elijah M Songok, PhD (1) · Gilberto De Nucci, MD (1) · Lalatendu Panigrahi (1) · Lawrency Parrish, MD (1)
PMID 25007364, PMID 21968664, PMID 22052309, PMID 23884486, PMID 30526582
2008 (1), 2015 (1)